Combining Serum DNA Methylation Biomarkers and Protein Tumor Markers Improved Clinical Sensitivity for Early Detection of Colorectal Cancer

Table 2

Positive detection rates of ColoDefense test for CRC of different ages, genders, tumor locations, and tumor sizes.

	Number ()	mSEPT9			mSDC2			mSEPT9+mSDC2
		Positive [ (%)]	Chi-square test		Positive [ (%)]	Chi-square test		Positive [ (%)]	Chi-square test
			Age
20-39	5	2 (40.0)	0.40	0.941	1 (20.0)	4.74	0.192	3 (60.0)	4.94	0.176
40-59	57	28 (49.1)			18 (31.6)			30 (52.6)
60-79	54	28 (51.9)			20 (37.0)			35 (64.8)
≥80	9	5 (55.6)			6 (66.7)			8 (88.9)
Gender
Male	79	43 (54.4)	1.40	0.238	27 (34.2)	0.31	0.578	49 (62)	0.14	0.713
Female	46	20 (43.5)			18 (39.1)			27 (58.7)
Tumor location
Proximal	23	11 (47.8)	0.00	0.999	9 (39.1)	1.50	0.473	14 (60.9)	0.02	0.992
Distal	23	11 (47.8)			6 (26.1)			14 (60.9)
Rectal	57	27 (47.4)			23 (40.4)			34 (59.6)
N/A	22	14 (63.6)	/	/	7 (31.8)	/	/	14 (63.6)	/	/
Tumor size
<3 cm	24	12 (50.0)	0.33	0.847	8 (33.3)	0.23	0.890	13 (54.2)	0.23	0.893
3-6 cm	74	34 (45.9)			25 (33.8)			44 (59.5)
≥6 cm	15	8 (53.3)			6 (40.0)			9 (60.0)
N/A	12	9 (75.0)	/	/	6 (50.0)	/	/	10 (83.3)	/	/

N/A: information not available. “/”: data not included in the Pearson chi-square test analysis.